Effect of oral probiotic in the treatment of psoriasis

Comparison of the effect of oral administration of probiotic strains with placebo on the clinical severity of psoriasis vulgaris

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140212016557N8

Enrollment

Registered

2021-10-03

Start date

2021-10-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis. psoriasis vulgaris

Interventions

Intervention 1: Intervention group: Daily consumption of Lactocare probiotic capsules (Zist takhmir company, Tehran, Iran), the once daily application of mometasone ointment on skin lesions and mometa

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Plaque type psoriasis 18 years of age or older Involvement of 20% or less of body surface area

Exclusion criteria

Exclusion criteria: Severe scalp psoriasis Worsening of signs and symptoms of psoriasis during treatment Pregnancy Lactation Consumption of any systemic treatment affecting psoriasis within the last three months before recruiting in the study Antibiotic administration within the recent two weeks Any signs and symptoms of bacterial infections Concomitant skin diseases Presence of significant liver diseases Presence of significant chronic kidney diseases Consumption of probiotic-containing products (including probiotic-containing foods)

Design outcomes

Primary

Measure	Time frame
Quantitative score of the clinical severity of psoriasis. Timepoint: At the beginning of treatment, months 1, 2, and 3 after treatment. Method of measurement: Psoriasis Area Severity Index (PASI) score.	—

Secondary

Measure	Time frame
Qualitative clinical severity of psoriasis. Timepoint: Months 1, 2, and 3 after treatment. Method of measurement: Physician global assessment score.;Quality of life. Timepoint: At the beginning and end of treatment. Method of measurement: Dermatology quality of life index questionnaire.;Percentage of acceptable improvement. Timepoint: Months 1, 2, and 3 after treatment. Method of measurement: Percentage of people who achieve equal to or more than ??% reduction in Psoriasis Area Severity Score.;Rate of improvement. Timepoint: Months 1, 2, and 3 after treatment. Method of measurement: Time of achievement of equal to or more than ??% reduction in Psoriasis Area Severity Score.	—

Measure

Time frame

Qualitative clinical severity of psoriasis. Timepoint: Months 1, 2, and 3 after treatment. Method of measurement: Physician global assessment score.;Quality of life. Timepoint: At the beginning and end of treatment. Method of measurement: Dermatology quality of life index questionnaire.;Percentage of acceptable improvement. Timepoint: Months 1, 2, and 3 after treatment. Method of measurement: Percentage of people who achieve equal to or more than ??% reduction in Psoriasis Area Severity Score.;Rate of improvement. Timepoint: Months 1, 2, and 3 after treatment. Method of measurement: Time of achievement of equal to or more than ??% reduction in Psoriasis Area Severity Score.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Nasiri

Shiraz University of Medical Sciences

amir_nasiri68@yahoo.com+98 71 3212 5239

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026